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General introduction 
Mitochondria are subcellular organelles found in all eukaryotic cells, except in 
red blood cells; they are implicated in multiple cellular processes and consist of 
two membranes, the inner mitochondrial membrane (IMM) and the outer 
mitochondrial membrane (OMM), and of two aqueous compartments, the matrix 
and the intermembrane space. The IMM area is several-fold larger than the one 
of OMM, due to the fact that in the IMM there are some invaginations called 
cristae which contain the electron transport chain complexes from I to IV 
(complex I, CI; complex II, CII; complex III, CIII; complex IV, CIV) and the F1-
F0-ATP synthase (CV). This multicomplex system is responsible for energy 
production, in the form of adenosine 5′-triphosphate (ATP), via the oxidative 
phosphorylation (OXPHOS). The transport of electrons, provided by carrier 
molecules such as NADH or FADH2, through the four complexes of the 
respiratory chain, with the help of two mobile electron shuttles (coenzyme Q and 
cyt c), generates energy, used by CI, CIII and CIV to pump protons across the 
IMM thus creating an electrochemical potential (ΔΨ). This electrochemical 
potential is the driving motor of the complex V and lead to the production of 
ATP, but is also responsible for the thermogenesis, the import of Ca2+ and the 
translocation of proteins inside the mitochondria (Ghezzi and Zeviani, 2018). 
Mitochondria contain a small circular multicopy genome (16569 base pair) 
(mitochondrial DNA (mtDNA)) that is maternally inherited and contains only 37 
genes encoding for 22tRNA, 2 rRNA and 13 proteins, which take part in the 
respiratory chain complexes, with the exception of CII. Based on the fact that 
each complex is composed by numerous additional subunits nuclearly-encoded, 
the assembly of each OXPHOS complex requires the insertion into IMM of both 
mtDNA- and nuclear DNA (nDNA) encoded subunits. Thus, the genetic basis of 
the OXPHOS is unique, with the involvement of both nuclear and mitochondrial 
DNA. 
In addition to energy production, mitochondria are involved in many biological 
functions, including the regulation of reactive oxygen species (ROS), biogenesis 
of the Fe-Cu clusters, heme synthesis, metabolism of amino acids and lipids, 
apoptosis and mitophagy (Gorman et al. 2016). Given their fundamental role in 
the physiology of the whole cell, mitochondria undergo to a tightly regulation, 
since any of their dysfunction can lead to dramatic consequences. 
Mitochondrial diseases (MDs) are a group of very heterogeneous and rare genetic 
disorders that affect mitochondrial respiratory chain function and cellular energy 
production. MDs can arise from both nuclear or mtDNA mutations, can occur at 
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any age and, although the most affected tissues are those with high energy 
demand such as brain, muscle and heart, the clinical signs could involve also 
liver, heart, kidney, eye and ear (Suomalainen and Battersby, 2018). The 
incidence of MDs is 1:5000 live birth (Gorman et al., 2016; Craven et al., 2017) 
considering only the mutation that affect the mtDNA and even higher by 
including some frequent nuclear gene mutations, reaching the incidence of 
1:2000 individuals (Suomalainen and Battersby, 2018). 
In the last years, the breakthrough of next-generation sequencing (NGS) 
approaches for genetic diagnosis has expanded the genetic heterogeneity of MDs 
(Stenton and Prokisch, 2018). More than 1,500 genes that are encoded in the 
nucleus, synthesize proteins targeted to mitochondria. Mutations can lead to 
mitochondrial dysfunction by different modes of transmission: sporadic, 
maternal, autosomal recessive, autosomal dominant or X-linked. Thus, 
mitochondrial diseases can follow any inheritance model, and are probably one 
of the most heterogeneous conditions known in the whole field of human genetic 
disorders. 
The maintenance of “healthy” and fully functional mitochondria is essential for 
cellular homeostasis. In this regard, the cell has evolved various mechanisms 
dedicated to the maintenance of the mitochondrial proteome such as 
mitochondrial dynamics and mitochondrial quality control. A first check point 
and active surveillance is provided by the organelle itself. The mitochondria have 
their own chaperones and proteolytic enzymes that remove damaged or unfolded 
proteins (Matsushima and Kaguni, 2012). The plasticity of the mitochondria 
allows continuous changes of their shape and number, while their morphology 
is maintained by the equilibrium of fusion and fission event. 
Mitochondria undergo fusion and fission in order to avoid damage accumulation 
or respond to certain bioenergetics demands (Campello and Scorrano, 2010). In 
recent years, a significant number of mutations in genes involved in 
mitochondrial dynamics and mitochondrial quality control have been recognized 
as the genetic cause of MDs. 
In our laboratory through the use of NGS technology we identify new mutations 
in genes involved in mitochondrial dynamics and in mitochondria quality control 
and we have functionally characterized these mutations and demonstrated their 
pathogenic roles in the analyzed patients. 
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Aims of the work 
The new mutations identified using the NGS technology expand the number of 
mutations on genes involved in mitochondrial dynamics and in mitochondria 
quality control. 
The main aim of my thesis is to characterize such mutations, proving their 
pathogenicity and demonstrate a genotype-phenotype correlation. The use of 
patients’ primary fibroblast as a cellular model has been a useful tool to verify 
the involvement of the mutated protein in specific pathways such as 
mitochondrial dynamics and mitochondrial quality control. In addition to 
histochemical and biochemical study, in vivo and in silico models have been 
applied. 
A basic understanding of the molecular mechanism involved in these 
mitochondrial pathways also can offer, in future, the opportunity to identify 
potential therapeutic targets in order to assess whether the use of new molecules 
could enable the recovery of the mitochondrial homeostasis and, therefore, the 
recovery of the phenotype as well. 
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Summary 
The maintenance of healthy and functional mitochondria is essential for cellular 
homeostasis; a first check point is provided by the organelle itself through the 
mitochondrial quality control and through the mitochondrial dynamics. One of 
the main players of the mitochondrial quality control is the Lon protease encoded 
by LONP1 gene, involved in mitochondrial proteostasis and in the maintenance 
of mitochondrial DNA. Mutations in LONP1 were associated with a multisystem 
disorder called CODAS (Cerebral, Ocular, Dental, Auricular, Skeletal) 
syndrome (Strauss et al. 2015) and, more recently, with a classical mitochondrial 
disease phenotype (Peter et al. 2018; Nimmo et al. 2019). Furthermore, 
mitochondrial dynamics involve the Drp1 protein, a large dynamin-like GTPases 
encoded by DNM1L gene, that is responsible for fission of mitochondria. 
Mutations in DNM1L gene have been associated with several neurological 
disorders (Schmid et al. 2019). 
Through the use of Next Generation Sequencing (NGS) technology, we 
identified new mutations in genes involved in mitochondrial quality control and 
dynamics. In one patient, we found three different mutations in LONP1, never 
described. These variants cause both energy defects and alterations in 
mitochondrial network. In five patients, we identified de novo dominant DNM1L 
variants, two of which have been never reported. Also in these cases, patients’ 
fibroblast displayed defects in mitochondrial morphology; interestingly, we 
observed, in muscle biopsies, changes in mitochondrial distribution. To date no 
peculiar histochemical alterations have been reported in DNM1L-mutated 
patients and this can represent a diagnostic tool. 
 
Sommario 
Il mantenimento dell’omeostasi cellulare è strettamente dipendente dai 
mitocondri, la cui funzionalità è innanzitutto regolata dall’organello stesso 
attraverso il controllo di qualità e il corretto network mitocondriale. Uno dei 
maggiori responsabili del controllo di qualità mitocondriale è la proteasi Lon 
codificata dal gene LONP1, coinvolta nella proteostasi e nel mantenimento del 
DNA mitocondriale. Mutazioni in questo gene sono state associate ad un 
disordine multisistemico noto come sindrome CODAS (Strauss et al. 2015). 
Recentemente, mutazioni in LONP1 sono state riconosciute come la causa di 
condizioni patologiche con caratteristiche cliniche associabili alle malattie 
mitocondriali (Peter et al. 2018; Nimmo et al. 2019). Nei processi della dinamica 
mitocondriale un ruolo fondamentale è svolto dalla dinamina Drp1, responsabile 
 Dottorato di Ricerca in Biologia Cellulare e dello Sviluppo 
5 
della fissione mitocondriale e codificata dal gene DNM1L. Mutazioni in questo 
gene sono state associate a diversi disordini neurologici (Fahrner et al. 2016). 
L’utilizzo di tecnologie di nuova generazione (NGS) ci ha permesso di 
identificare nuove mutazioni in geni coinvolti nel controllo di qualità e nella 
dinamica mitocondriali. In un paziente abbiamo riscontrato tre diverse mutazioni 
in LONP1, mai finora descritte. Le varianti identificate determinano sia difetti 
energetici che alterazioni del network mitocondriale. In altri cinque pazienti, 
abbiamo invece individuato varianti de novo nel gene DNM1L, due delle quali 
non sono mai state riportate. Anche in questo caso nei fibroblasti dei pazienti 
abbiamo osservato difetti della morfologia mitocondriale, mentre nel tessuto 
muscolare abbiamo riscontrato alterazioni della distribuzione dei mitocondri a 
livello delle fibre muscolari. È importante sottolineare che tali alterazioni 
istopatologiche non erano mai state osservate in precedenza e possono 
rappresentare un tratto diagnostico per la ricerca di mutazioni nel gene DNM1L. 
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I PART 
Introduction 
Mitochondrial fission and fusion are essential mechanisms, known as 
mitochondrial dynamics, involved in the regulation of the cellular homeostasis. 
Once mitochondria were considered “static bean-shaped” organelles, but now it 
is well established that mitochondria assemble into a network that is very dynamic 
and undergoes dimensional and structural changes to meet specifics energy needs 
of the cell. Since mitochondria are dynamic organelles, capable of fusion, 
fragmentation, biogenesis, mitophagy, and intra- or inter- cellular transport, the 
overall state of the mitochondrial network and its distribution within a cell are 
fluid (Valente et al, 2019). 
Mitochondrial dynamics are driven by a set of dynamin’s family members, the 
large guanosines triphosphate hydrolases (GTPases) that are well conserved 
between yeast, flies, and mammals. Fission is mediated by a cytosolic dynamin 
family member called Drp1, encoded by DNM1L gene. When activated DRP1 is 
recruited by the mitochondrial dynamics’ proteins 49 and 51 kDa (MiD49 and 
MiD51), and the mitochondrial fission factor (Mff) to the outer mitochondrial 
membrane, where it binds its receptor, the mitochondrial fission protein 1 (Fis1) 
and multimerizes, creating a ring-like structure that constricts and divides the 
organelle. Moreover, Drp1 is also involved in the perossisomal fission, acting 
with a similar mechanism division (Schrader et al., 2016). Opposed to fission, 
fusion between mitochondrial fusion between mitochondrial inner membranes is 
mediated by a single dynamin family member called Opa1, whereas fusion of the 
outer membranes is mediated by membrane-anchored dynamin family members 
named mitofusins (Mfn1 and Mfn2) (Youle et al. 2012). 
Mitochondrial fission and fusion machineries are regulated by proteolysis and post-
translational modifications. In particular the regulation of DRP1 by post-
translational modifications is important for DRP1 translocation to mitochondria. 
Phosphorylation of DRP1 at Ser 616 (S616) by cyclin dependent kinase (CDK) 
1/Cyclin B or CDK5 promotes mitochondrial fission during mitosis. In contrast, 
DRP1-S637 phosphorylation by protein kinase A (PKA) induces the detachment 
of DRP1 from mitochondria and inhibits mitochondrial fission (Pagliuso, Cossart 
and Stavru, 2018). It is demonstrated that mitochondrial fission is essential for 
growing and dividing cells to populate them with adequate numbers of 
mitochondria and to ensure the presence of mitochondria at sites of high ATP 
consumption. Knockout studies in mice showed that deletion of Drp1 is 
embryonically lethal, indicating that mitochondrial fission is an essential process  
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(Ishihara et al., 2009). At a cellular level, mitochondrial fission is important for 
organelle distribution during mitosis (Horbay and Bilyy, 2016) and for proper 
distribution of mitochondria to neuronal synapses, where localized energy 
production supports synaptic functions (Wakabayashi et al., 2009). 
A fine regulation between fission and fusion is needed to a proper mitochondrial 
function and alterations in genes involved in the process of mitochondrial 
dynamics is related to many human diseases. Up to date mutations have been 
found in the following genes: 
 
• MFN2 (OMIM#609260), associated with the peripheral neuropathy Charcot–
Marie–tooth disease type 2a (Stuppia et al., 2015); 
• OPA1 (OMIM#165500), that lead to the autosomal dominant optic atrophy 
(ADOA), a pathological condition characterized by the loss of some or most of the 
fibres of the optic nerve (Lenaers et al., 2012); 
• OPA3 (OMIM#258501), associated Optic Atrophy and increased excretion of 3- 
methylglutaconic acid (Ankister et al. 2001); 
• GDAP1 (OMIM#607831), mutations in this gene cause the Charcot–Marie–Tooth 
2K (Chunget al. 2008); 
• MIEF2 associated with mitochondrial myopathy (Bartsakoulia et al., 2018). 
 
DRP1 impairment, associated with either de novo dominant or compound 
heterozygous mutations (MIM #603850), is implicated in several neurological 
disorders characterized by early onset encephalopathy, psychomotor delay, 
hypotonia, progressive course and death in childhood. Many patients develop 
refractory seizures, consistent with an epileptic encephalopathy, and thereafter 
show neurological decline. Cultured fibroblasts from patients with these genetic 
conditions usually show abnormally elongated mitochondria and aberrant 
peroxisomes (Fahrner et al., 2016; Nasca et al., 2016). 
In this thesis, I describe five patients affected by severe epileptic encephalopathy 
associated with de novo dominant mutations in DMN1L, three of which never 
reported before. Cultured fibroblasts displayed the classical altered mitochondrial 
and peroxisomal network; moreover, mitochondrial alterations have been 
observed in the muscle biopsy. The muscle’s peculiarity has been for the first time 
associated with mutations in DNM1L. 
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Results 
Case reports 
The patients described here are affected by early onset encephalopathy with 
microcephaly and drug resistant seizures, progressive brain atrophy or abnormal 
brain development, and occasionally persistent lactic acidemia. 
Mutational analysis 
Bioinformatics analysis carried out on the TruSight One panel (for Pt.1, Pt.2 and 
Pt.3) and on a targeted mitochondrial panel (for Pt.4 and Pt.5) led to the 
identification of a single gene entry, DNM1L (NM_012062, NP_036192). Six 
different mutations have been detected in DNM1L (NM_012062), all resulted 
absent in public (dpSNP142, ExAC, 1000 Genomes, HGMD, gnomAD) and in-
house databases. The identified variants are reported in Table 1. 
 
 
Patient 
 
Mutation 
 
Aminoacid 
change 
 
Segregation 
 
References 
 
Pt.1 
c.668G>T p.Gly.223Val de novo - 
 
Pt.2 
 
c.1207C>T 
 
p.Arg403Cys 
 
de novo 
Fahrner et al., 
2016; Schmid 
et al., 2019 
 
Pt.3 
 
c.1109T>G 
 
p.Phe370Cys 
 
de novo 
 
- 
 
Pt.4* 
 
c.1085G>A 
c.1535T>C 
 
p.Gly362Asp 
p.Ile512Thr 
 
de novo (?) 
mother 
- 
Vanstone et 
al., 2016 
Pt.5 c.1084G>A p.Gly362Ser de novo 
Sheffer et al., 
2015 
Table 1: The variants have been identified by NGS and confirmed by Sanger 
sequencing in all patients and their parents. In Pt.4 the first variant c.1085 G>A is 
a de novo event and the second variant c.1535 T>C was inherited from the mother. 
SIFT (http://sift.jcvi.org) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) 
were used for pathogenicity prediction of the variants. 
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Segregation in the families was negative for all mutations (Figure 1A-E), and 
this speak for a de novo event, except for the p.Ile512Thr identify in Pt.4 
which was inherited from the mother (Figure 1D’). An in-depth evaluation 
of the familiar history of Pt.4 revealed that the mother had a son with epileptic 
encephalopathy from another man. This child died at 3 years of age and no 
material was available for genetic studies. By subcloning PCR products 
obtained from Pt.4’s cDNA, we were able to assess that the two DNM1L 
variants were on the same allele (i.e., the maternal allele). Moreover, a further 
analysis of DNM1L genomic region using a next- generation sequencing 
(NGS) approach revealed that the c.1085G>A was present in the mother’s 
blood DNA, although at very low level (~5%) (Figure 2 A-B). These findings 
suggested a maternal germline mosaicism for the dominant mutation 
c.1085G>A (p.Gly362Asp), that may even explain the affected status of the 
Pt.4’s half-brother. 
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Figure 1 Electropherograms. The variants identified by NGS in DNM1L (A-E) have 
been confirmed by Sanger sequencing in all patients and their parents. In D’ the 
second variant identified in Pt.4 (c.1535T>C) was inherited from the mother. 
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Figure 2: Segregation analysis in the family of Pt.4. (A) NGS analysis revealed 5% 
c.1085G>A variant in blood DNA from Pt.4’s mother, indicating germinal mosaicism. (B) 
Pedigree and reconstruction of the DNM1L alleles in Pt.4’s family members. Genotypes 
under brackets are hypothesized but not tested because DNA was not available. 
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Histological and biochemical analyses 
Histochemistry of the muscle sample of Pt.1, Pt.2, Pt.3 showed scattered 
fibers with a patchy reduction of cytochrome c oxidase (COX) and succinate 
dehydrogenase (SDH) stain with aspects of polymorphic core like areas 
(Figure 3, left and central panels). Similarly, areas of reduced 
immunoreactivity were observed using the TOMM20 antibody confirming 
impairment of the mitochondrial network distribution (Figure 3, right panel). 
Moreover, histochemical serial sections of the muscle biopsy in Pt. 3 showed 
that the fibers devoid of mitochondria were type 1 fibers (Figure 4). In Pt.4 
histochemical examination of muscle tissue’s mitochondria using electron 
microscopy revealed abnormal mitochondria that couple each other (Figure 
5). OXPHOS biochemical analysis in muscle homogenate was normal in Pt.1, 
Pt.2, Pt.3 and Pt.4 (data not shown). Histochemistry of the muscle sample of 
a patient affected by an autosomal recessive mutation in OPA1 (Nasca et al., 
2017) was studied and compared with those of DNM1L patients and showed 
no patchy staining abnormalities (Figure 3 lowest panel). 
In addition, by Long Range PCR we also searched comparatively for multiple 
deletions in muscle samples and found multiple deletions only in the OPA1 
mutated patient and no in the DNM1L patients (data not shown).
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Figure 3: Panel showing the histochemistry of quadriceps muscle samples of 
Pt.1, Pt.2, Pt.3 and control. The muscle histochemistry of serial sections of three 
patients with heterozygous dominant mutations in DNM1L and stained with 
cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) showed scattered 
fibers with a patchy reduction of both COX and corresponding SDH, with aspects of 
polymorphic core like areas (left and central panel). Similarly areas of reduced 
immunoreactivity was observed using the TOMM20 antibody confirming impairment of 
the mitochondrial network distribution (right panel). These abnormalities were not 
detected in the muscle biopsy of a patient with biallelic mutations in OPA1 (last bottom 
row) already described (Nasca et al., 2017). 
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Fig.4: Histochemistry of the muscle biopsy of Pt.3 showing that serial fibers stained 
for COX (A), SDH (B), NADH (C) and ATPase 9.4 (D) that are devoid of mitochondria 
(arrows) are all type 1 fibers. 
 
 
Fig.5: Histopathological aspects of the muscle biopsy of Pt.4. Electron microscopy 
shows enlarged mitochondria, which sometimes appear connected to each other. 
Original magnification 30000X.
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Western blotting analysis 
To evaluate the impact of the mutations on DRP1 stability, we performed WB 
analysis on fibroblasts. We observed a significantly increased (in Pt.3) or normal 
(in Pt.1, Pt.2, Pt.4 and Pt.5) level of the protein when normalized to GAPDH 
(Figure 6A-B), in contrast with the strong reduction present in DNM1L-recessive 
cases (Nasca et al., 2016). The expression level of OPA1 and of different subunits 
of the OXPHOS showed no differences compared to controls (data not shown). 
Figure 6 Western blotting analysis. Immunoblot analysis of total lysates from control 
subjects (Ct) and patient’s (Pt) fibroblasts using α-DRP1, α-VDAC, and α-GAPDH 
antibodies. The latter was used as loading control. The state level of DRP1 protein is 
significantly increased in Pt.3 fibroblasts. Values in the graph are given as the mean ± 
SD (n = 4 to 5); *, p<0,05. 
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Tissue culture, Immunostaining and Imaging 
Because of the pivotal role of DRP1 on dynamics of mitochondria and 
peroxisomes, we performed morphological studies on patients’ fibroblasts. In 
normal glucose medium Pt.1 displayed a mixed population in which hyperfused 
mitochondria are associated with swollen and rod-shaped mitochondria and Pt.5 
showed dot-shaped mitochondria (Figure 7A-B, left panel). In galactose-
supplemented medium the mitochondrial network of DNM1L-mutant fibroblasts 
showed a lower tendency to fuse associated with a more disorganized network 
with swollen, dots, rings, and “chain-like” structures (Figure 7A-B, right panels). 
For the immuno- staining of peroxisomes, we used an antibody against PMP70 
and organelles appear longer, larger, and less uniformly distributed into cytoplasm 
in Pt.4 and Pt.5 in contrast with the highly diffused punctuated staining present in 
control cells (Figure 7C). 
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Figure 7: Characterization of the mitochondrial and peroxisomal network: analysis 
by fluorescence microscopy. (A-B): We used the antibody TOMM20 in fixed cells for 
Pt.1 or Mitotracker red in living cells for Pt.5, both specific for mitochondrial staining. 
(C): Immunofluorescence staining with the anti-PMP70 antibody of fibroblasts from Ct, 
Pt.4 and Pt.5 (Scale bar: 25 μm). 
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Functional studies in yeast 
The deleterious effect of the p.Arg403Cys substitution was already 
experimentally demonstrated (Fahrner et al. 2016). To assess the pathogenic role 
of the other identified DNM1L variants as well as to compare the effects of 
different substitutions on the same amino acid (p.Gly362), we performed 
complementation studies in a S. cerevisiae strain lacking DNM1, hereafter 
referred to as Δdnm1. DNM1 is the yeast orthologue of human DNM1L; the amino 
acid residues corresponding to p.Gly223Val, p.Gly362Asp, p.Gly362Ser and 
p.Ile512Thr variants are conserved between the two species, being in yeast 
p.Gly252, p.Gly397, p.Ile543, whereas human p.Phe370 is not conserved, being 
p.Tyr405 in yeast. The dnm1Δ strain was transformed either with the wt DNM1, 
the dnm1G252V, dnm1G397D, dnm1G397Sor dnm1I543T mutant alleles, under 
the endogenous DNM1 promoter, as well as with the empty plasmid. To test the 
possible effects on mitochondrial function, we first evaluated the oxidative growth 
by spot assay analysis on medium supplemented with either glucose or ethanol or 
glycerol. The oxidative growth of the dnm1G397D and the dnm1G397S mutant 
strains was partially affected compared to the DNM1 wild type strain whereas the 
growth of the dnm1G252V was similar to the strain dnm1Δ; on the contrary the 
growth of the dnmII543T mutant was unaffected (Figure 8A). To further 
investigate the OXPHOS defect, the oxygen consumption was measured and 
according to the growth phenotype, the oxygen consumption rate of the 
dnm1G397D and of the dnm1G397S mutants was respectively 30% and 20% 
lower than that of the wild type strain, whereas the oxygen consumption rate of 
dnm1G252V and of the dnm1 null strain was decreased by 60%; also, the 
dnmII543T mutant showed a slight though significant reduction of respiratory 
activity (Figure 6B). Altogether these results validated the pathogenicity of the 
mutations Gly252Val, Gly397Asp and Gly397Ser, showing also that substitution 
of Gly397 with aspartate is more deleterious than substitution with serine. The 
amino acid change Ile543Thr slightly affects the activity of the protein too, being 
the respiratory activity altered compared to DNM1 wild type. Since the variant 
Ile512Thr was present in the patient in cis with the Gly362Asp, we also 
constructed a yeast mutant allele carrying both the corresponding variants. 
Interestingly, the dnm1G397D-I543T strain showed a more severe phenotype than 
the strain carrying only the mutation Gly397Asp; in fact, the oxidative growth and 
the respiratory activity become similar to that of the null mutant suggesting that 
Ile543Thr is a phenotypic modifier (Figure 8A-C). 
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Finally, we tested whether the mutations have a dominant or recessive effect using 
a diploid hemizygous DNM1/dnm1 strain transformed with the plasmid having 
mutant alleles or with the empty vector and measuring the oxygen consumption. 
The respiratory activity of the heteroallelic strains DNM1/dnm1G397D, 
DNM1/dnm1G397S and DNM1/dnm1G397D-I543T, but not that of 
DNM1/dnm1G252V and DNM1/dnm1I543T, was lower compared to the 
hemizygous strain DNM1/dnm1. This indicates that Gly397Asp and Gly397Ser 
have a partial dominant-negative effect whereas Ile543Thr and, quite 
unexpectedly, Gly252Val act as recessive mutations (Figure 8C), at best 
concerning the effect on oxygen consumption. To better deepen this point, we 
investigated in the heteroallelic strain DNM1/dnm1G252V another phenotype, i.e 
the petite frequency, based on the observation that the mutation Lys41Ala, 
generally recognized as dominant (Frank et al., 2001), increased the petite 
frequency in an heteroallelic diploid mutant strain (Nasca et al., 2016). The 
significant increase (3.3-fold±0.6, p<0.001) of the petite frequency observed, 
compared to the hemizygous strain, suggests that also the Gly252Val mutation 
behaves as partially dominant, at least for this specific phenotype (Figure 8D). 
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Figure 8: Functional study in yeast. (A) Phenotypic analysis of haploid strains 
through spot assay. Serial cell dilutions of dnm1Δ haploid strain transformed with 
DNM1 wt or mutant alleles were spotted on Synthetic complete medium supplemented 
with either 2% glucose or 2% glycerol. (B) Respiratory activity of dnm1Δ haploid strain 
transformed with DNM1 wt or mutant alleles. *(p<0.05), **(p<0.01) and ***(p<0.001).
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Figure 8: Functional study in yeast. (C) Respiratory activity of DNM1/dnm1Δ diploid 
strain transformed with DNM1 wt or mutant alleles. (D) petite frequency of 
DNM1/dnm1Δ diploid strain transformed with DNM1 wt or mutant alleles. *(p<0.05), 
**(p<0.01) and ***(p<0.001).
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Structural analysis 
All the identified missense mutations affect sites, which are totally or highly 
conserved sites among species (Figure 9A) and imply replacements with residues 
presenting physicochemical properties that differ significantly from those of the 
wild type amino acids. The Gly223Val mutation causes the substitution of the tiny 
and flexible glycine with a hydrophobic valine, which is expected to induce 
structural changes in the GTPase domain near residues 215-221 important for the 
binding of GTP (Figure 9B). The Gly362Asp and Gly362Ser mutations replace 
the tiny glycine with the anionic aspartic acid or with the hydrophilic serine, 
respectively, modifying the N-terminus of an α-helix also exploited in dynamin 
tetramerization (Figure 9C), as inferred by homology of dynamin-1-like with 
dynamin 3, another member of the dynamin family. The Phe370Cys mutation 
affects the large and hydrophobic phenylalanine that is important for the stability 
of monomers and for the tetramer formation (Figure 9D). In fact, Phe370 is 
involved in several intramolecular hydrophobic interactions, which are disrupted 
by the replacement with the small cysteine and the latter might also become 
engaged in disulfide bond formation with other cysteines located nearby. The 
Arg403Cys mutation implies the change of the cationic arginine into the tiny and 
neutral cysteine at sites that contribute to the core of tetrameric dynamin assembly 
(Figure 9E), as previously reported (Fahrner et al., 2016).
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Figure 9: Conservation and structural mapping of residues affected by the 
missense mutations G223V, G362D, F370C, and R403C. (A): multiple sequence 
alignment among species (invariant columns are grayed). Structural mapping of 
residues affected by the missense mutations G223V, G362D, F370C, and R403C. 
Mapping of G223 (B) on the crystal structure of a dimeric human dynamin- 1-like protein 
(PDB 3W6O). Mapping of G362 (C), F370 (D), and R403 (E) on dynamin tetramer 
(PDB 5A3F). 
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Discussion 
The use of NGS technology allowed us to described four patients with de novo 
dominant missense mutations in DNM1L. All the patients presented some 
classical features of mitochondrial disease such as early symptoms of 
encephalopathy, developmental delay, drug resistant seizures and, only in Pt.2 and 
Pt.5, blood lactic acidemia. 
We identified two novel variants in Pt.1 and Pt.3, whereas in Pt.2 and Pt.5 we found 
two variants that were already reported (Fahrner et al., 2016; Sheffer et al., 2015). 
Pt.4 showed two variants on the same allele; the first was inherited from the 
mother and the second, recently described as a de novo mutation (Vanstone et al., 
2016), was present in the mother’s blood DNA at low level (~5%), suggesting a 
maternal mosaicism. We observed a quite strict genotype-phenotype correlation, 
with overlapping clinical presentations between Pt.2, Pt.4, Pt.5 and the previously 
described patients harboring the same mutation (reported by Fahrner et al., 
Vanstone et al. and Sheffer et al., respectively). 
Following the first description of Waterham et al., there have been increasing 
reports in the last 2 years on patients, frequently sporadic, with de novo dominant-
negative DNM1L mutations who are affected by early onset encephalopathy with 
microcephaly and drug resistant seizures, progressive brain atrophy or abnormal 
brain development, optic atrophy, and occasionally persistent lactic acidemia 
(Fahrner et al., 2016; Schmid et al., 2019; Sheffer et al., 2015; Longo et al.2019). 
The patients described here presented clinical manifestations quite similar to 
previously reported DNM1L cases. 
Probably the most peculiar finding in the cohort of our patients is the muscle 
histology/histochemistry showing core like areas using oxidative enzyme staining 
for COX and SDH, which suggest an abnormal distribution of mitochondria in the 
muscle tissue. We found this pattern in all the examined muscle biopsies. 
Moreover, in serial sections of muscle fibers of Pt.3 we demonstrated that the 
fibers that are no reactive for COX, SDH and NADH are also negative for the 
staining with ATPase 9.4 indicating that these are type I muscular fibers. In 
addition, the EM in Pt.4 showed enlarged mitochondria, sometimes two 
mitochondria were coupled and appeared to be in close relationship to each other. 
Areas devoted of mitochondria has not been found in muscle biopsies of OPA1 
mutated patients that, sometimes, showed ragged red-COX negative fibers 
correlated with mitochondrial DNA instability (Amati- Bonneau et al., 2008). Our 
findings are new for DNM1L patients; in fact, no histochemical alteration has ever 
been reported, and only once abnormalities in mitochondrial cristae were 
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observed (Vanstone et al., 2016). 
At the cellular level, using fluorescence microscopy, we found the presence of 
hyperfused, swollen and rod-shaped mitochondria in fibroblasts from all our 
patients, as reported for others DNM1L mutations (Waterham et al., 2007, Fahrner 
et al., 2016; Zaha et al., 2016; Sheffer et al., 2016; Vanstone et al., 2016; Nasca 
et al., 2016; Gerber et al., 2017; Longo et al.2019). The morphological anomalies 
were not associated with OXPHOS dysfunctions, in fact we did not observe 
reduction of OXPHOS subunits levels. The same findings have been reported in 
most of the DNM1L-mutant cases. Moreover, these results are consistent with the 
one obtained in muscle sample, in which the activities of the respiratory chain 
complexes were also normal. 
In addition to mitochondrial fission, DRP1 is also implicated in the peroxisomes’ 
division (Schrader et al., 2016); to this purpose we investigated peroxisomal 
morphology and in fibroblasts from Pt. 4 and Pt. 5 we observed organelles longer, 
larger, and less uniformly distributed into cytoplasm, in contrast with the highly 
diffused punctuated staining present in control cells; the same condition has been 
described for other patients with mutations in DNM1L (Waterham et al., 2007; 
Nasca et al., 2016; Zaha et al., 2016). 
DRP1 protein consists of four conserved regions: the GTPase domain, the middle, 
the variable, and the GTPase effector domain (GED). In the cytosol, DRP1 exists 
as a mixture of dimers and tetramers (Macdonald et al., 2014) and, when recruited 
to mitochondria via receptors anchored to the mitochondrial outer membrane 
(Losón et al., 2013), hydrolysis of GTP triggers conformational changes in DRP1 
oligomers that generate the mechanical force to promote mitochondrial membrane 
scission (Francy et al., 2015). The middle and GED domains promote DRP1 self-
assembly, required for mitochondrial fission (Chang et al., 2010), while the 
variable domain seems to act as a negative regulator of DRP1 self-assembly 
(Francy et al., 2015). 
We noted that mutations that fall into the GTPase domain are typically associated 
with a recessive trait, except for the cases not associated with early 
encephalopathy, reported by Gerber et al., 2017, while mutations that fall into the 
middle domain are expressed as dominant- negative. In only one of our patients 
(Pt. 1) we identified a mutation (p.Gly223Val) which falls into the GTPase 
domain, even if the nucleotide exchange is located at the boundary between the 
GTPase and the central domain. 
Using the in silico structural model we demonstrated that the Gly223Val (Pt.1) 
mutation induces structural changes in the GTPase domain; while the remaining 
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mutations affect the stability of monomers and the tetramer formation. 
Finally, the S. cerevisiae model confirmed the pathogenicity of all variants. 
Moreover, we demonstrated for all the mutations a dominant negative effect and 
that the second mutation (p.Ile512Thr) of the Pt.4 act as a modifier, able to worsen 
the phenotype associated with the p.Gly362Asp mutation. 
In conclusion, in this part of this thesis, we have described six variants in DNM1L 
gene, two of which has never been reported. Also, we confirmed their 
pathogenicity and expanded the spectrum of the mutations occurring in this gene; 
finally, we observed for the first time a peculiar alteration in muscle specimen 
never associated before with mutations in DNM1L. 
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Methods 
Standard protocol approvals, registrations and patients consents 
The study was approved by the Ethical Committees of the Bambino Gesù 
Children’s Hospital, Rome, Italy, and the C. Besta Neurological Institute, Milan, 
Italy, in agreement with the Declaration of Helsinki. 
Histological, ultrastructural and biochemical analyses 
Cryostatic cross-sections of quadriceps muscle biopsies were processed according 
to standard histochemical and immunohistochemical procedures. Respiratory 
chain complexes (RCCs) activities were assayed in muscle homogenate and 
normalized to citrate synthase activity, using a previously reported 
spectrophotometric method (Bugiani et al., 2004). For ultrastructural studies, 
muscle specimens were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer 
(pH 7.4) at 4°C. Samples were post-fixed with 2% OsO4 in 0.1 M cacodylate 
buffer (pH 7.4) for 1 
h. Specimens were dehydrated in a graded series of ethanol and embedded in epon 
resin. Thin sections were evaluated with a transmission electron microscope (EM 
109 Zeiss) (Fattori et al., 2018). 
Mutational analysis 
Genomic DNA was isolated from blood and cultured skin fibroblasts using 
QIAamp DNA mini kit (QIAGEN, Valencia, CA, USA). DNA from Pt.1, Pt.2 and 
Pt.3 underwent high-throughput sequencing by TruSight One panel (Illumina, San 
Diego, CA) comprehensive of > 4.800 clinically relevant genes. The enrichment 
was achieved following manufacture instruction and the sequencing analysis was 
performed on MiSeq System. Variant-Studio software was applied for analysis, 
classification, and reporting of genomic variants. After excluding previously 
annotated single nucleotide changes occurring with high frequency in populations 
(>1%), we prioritized variants predicted to have functional impact (i.e. 
nonsynonymous variants and changes affecting splice sites). Pt.4 and Pt.5 were 
analyzed using a custom gene panel for the screening of 224 genes associated with 
mitochondrial diseases (Ardissone et al., 2018). Sanger sequencing was used to 
validate all the annotated functionally relevant variants, as well as to check 
variant segregation in the families. Bioinformatics tools based on heuristic 
methods, SIFT (http://sift.jcvi.org) and PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2), were used for pathogenicity prediction of 
the variants. 
Western blotting analysis and antibodies 
For SDS-PAGE, 40 μg of fibroblasts homogenate were loaded in a 12% 
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denaturating gel. Western blot (WB) was achieved by transferring proteins onto 
polyvinylidene difluoride (PVDF) membrane and probed with specific antibodies. 
Specific bands were detected using Lite A blot Extend Long Lasting 
Chemiluminescent Substrate (Euroclone, Pero (Mi), Italy). Densitometry analysis 
was performed using Quantity One software (BioRad, Hercules, CA, USA). 
RCC subunits were detected using the following monoclonal antibodies 
purchased from MitoScience (Eugene, OR, USA): Complex I – NDUFA9; 
complex II – SDHB; complex IV – COXII; Complex V – ATP5B; porin (VDAC). 
Polyclonal rabbit GAPDH (Sigma-Aldrich), monoclonal antibody OPA1 (BD 
Biosciences) and DRP1 (Abcam) were also used. 
Tissue culture, Immunostaining and Imaging 
Human fibroblasts were obtained from a diagnostic skin biopsy and grown in 
DMEM medium supplemented with 10% fetal bovine serum, 4.5 g/L glucose, and 
50 μg/mL uridine. 
To display the mitochondrial network arrangement, fibroblasts from Pt.1, Pt.2, 
Pt.3 were fixed and permeabilized using methanol:acetone (2:1) for 10 min at 
room temperature, then a blocking solution containing 5% BSA in PBS was used. 
The polyclonal rabbit TOMM20 antibody (Santa Cruz Biotechnology) was 
applied overnight and visualized using Alexa Fluor 647 secondary antibody 
(Jackson Immuno Research), both antibodies were used at the dilution of 1:500. 
Images were acquired with a fluorescence-inverted microscope (Leica DMi8). An 
average of 8 image planes was obtained along the z-axis at 0.2 μm increments 
using LASX 
3.0.4 (Leica) software. Mitochondrial depolarization was induced using 20 μM 
protonophore carbonyl cyanide m-chlorophenyl hydrazine (CCCP) for 3 hours. 
For Pt.4 and Pt.5 the mitochondrial network was visualized in living cells using 
the mitochondrial fluorescent dye MitoTracker Red-CMXRos (Invitrogen) at 
final concentrations of 50 nM for 30 min; then images were acquired with a 
confocal microscope (Leica TSC-SP8). For peroxisomal immunostaining we used 
the polyclonal rabbit PMP70 antibody (Sigma-Aldrich) applied overnight at the 
concentration of 1:200, followed by Alexa Fluor 488 secondary antibody (1:500). 
The peroxisomal staining was visualized using the same parameters used above. 
Statistical analysis 
For each experiment, data obtained were calculated as the mean of replicates ± 
standard deviation (SD). 
Structural analysis 
The residues affected by the missense mutations described in this work 
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(p.Gly223Val, p.Gly362Asp, p.Phe370Cys, and p.Arg403Cys) were mapped on 
crystal structures of homologues proteins. The crystal structure of a dimeric 
human dynamin-1-like protein (Protein Data Bank, PDB, 3W6O) was used for the 
p.Gly223Val mutation. The crystal structure of the Dynamin-3 tetramer (PDB 
5A3F) was used for the p.Gly362Asp, p.Phe370Cys, and p.Arg403Cys mutations. 
The cryo-electron microscopy structure of human dynamin-1 co- assembled with 
MID49 (PDB 5WP9) was used to obtain the detailed view of the site of the 
p.Phe370Cys mutation. Molecular structures were rendered with PyMOL 
(http://www.pymol.org). 
Functional studies in yeast 
Yeast strains and media. The yeast strains used in this work were the haploid strain 
W303-1B (MATa leu2-3, trp1-1, can1-100, ura3-1, ade 2-1, his3-11) and its 
isogenic strain dnm1::KanR, and the hemizygous diploid strain W303 dnm1_ 
(MATa/MATa leu2-3/leu2-3, trp1-1/trp1-1, can1- 100/can1-100, ura3-1/ura3-1, 
ade 2-1/ade2-1, his3-11/his3-11 DNM1/dnm1::KanR). All experiments were 
performed in Synthetic complete medium (SC, 6.9 g/l yeast nitrogen base 
without amino acids (ForMedium), 1 g/l drop-out mix without amino acids or 
bases necessary to keep plasmids) (Kaiser et al., 1994). Media were supplemented 
with carbon sources (Carlo Erba Reagents) as indicated in the text in liquid phase 
or after solidification with 20g/L agar (ForMedium). Construction of dnm1 
mutant strains. dnm1 mutant alleles and dnm1 mutant strains were 
constructed as previously reported (Nasca et al., 2016). Briefly, dnm1 mutant 
alleles were constructed using mutagenic overlap PCR with the oligonucleotides 
reported in Supplementary Table S1, digested with BamHI and XbaI or XbaI and 
SalI, and subcloned in pFL38DNM1. In order to obtain haploid wild type or 
mutant strains all plasmids were introduced by transformation in the W303-1B 
dnm1' haploid strain and in the W303 dnm1' hemizygous diploid strain using the 
“LiAc/SS carrier DNA/PEG quick method” as previously reported (Gietz & 
Woods, 2002). Yeast analyses. Spot assay was performed by spotting 5x104, 
5x103, 5x102 and 5x101 cells on SC supplemented with different carbon sources. 
Petite frequency was measured as previously reported (Baruffini et al., 2010) in 
six to eight independent clones for each strain. Oxygen consumption rate was 
measured in SC medium as previously described (Goffrini et al., 2009) on five 
independent clones, after growth in conditions, which minimized the petite 
frequency, which was lower than 5%. (Nolli et al., 2015). All experiments were 
performed at 37°C, except for the measurement of the petite frequency in the 
diploid strains, which was performed at 28°C 
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II PART 
Introduction 
Lon is a 959-residue long serine protease, encoded by the nuclear gene, LONP1, 
conserved among prokaryotes and eukaryotes; it belongs to the AAA+ protein 
family (ATPases Associated with a wide variety of cellular Activities) and is one 
of the main actors of the mitochondrial quality control. The protein is composed 
of four distinct domains: the mitochondrial target sequencing domain (MTS) 
which direct the localization of Lon to the mitochondrial matrix, the substrate 
recognition domain, the ATPase domain which bind ATP and the proteolytic 
domain (Fig.9A). The structure of Lon in human has been solved by X-ray 
crystallography only for the proteolytic domain and it has been observed that it 
has the same structural layout of bacterial and archaeal Lon protease, showing an 
active site with a Ser-Lys dyad (S855-K898). In its activated state Lon forms a 
quaternary structure as a homo-hexamer in which ATPase and proteolytic 
domains occupy the head region of the hexamer while the substrate binding 
domain the leg’s region (Fig.9B). The proteolytic activity of Lon is driven by 
conformational changes resulting from the binding and hydrolysis of ATP, 
mediated by its ATPase domain. 
The maintenance of mitochondrial health and function is provided by a set of 
chaperones and proteases, located in different mitochondrial compartments, which 
control the biosynthesis, folding or degradation of misfolded proteins. The AAA+ 
proteases are specifically located as follow: in the mitochondrial matrix are 
present Lon and the ClpXP (Caseinolytic Mitochondrial Matrix Peptidase) 
complex, in the IMM the intermembrane the (i-AAA) protease YMEIL1L, and 
the AFGL3L2 and paraplegin are inserted into the IMM and facing the matrix. 
Lon, in the mitochondrial matrix, acts mainly as a protease but also as a chaperone 
to guide the folding of several respiratory chain complexes subunits (Rep et al., 
1996). Moreover, it can regulate the stability of the mtDNA, directly binding it 
(Fu, Smith & Markovitz, 1997; Fu & Markovitz,1998) or indirectly regulating the 
degradation of the main transcription factor of the mtDNA, TFAM (Lu et al., 
2007). Several experiments have shown the functional involvement of the Lon 
protein in ageing, as well as in tumorigenic transformation (Luciakova et al., 
1999; Luce and Osiewacz, 2012). 
LONP1 mutations have been associated to a severe disease, known as CODAS 
(Cerebral, Ocular, Dental, Auricular, Skeletal anomalies) (Shebib et al., 1991; 
Strauss et al., 2015) (OMIM #600373). Only recently LONP1 mutations have been 
recognized as the genetic cause of a subtype of mitochondrial disease (Peter et al., 
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2018; Nimmo et al., 2019). 
In our laboratory the use of NGS technology allowed us to identify three different 
mutations in LONP1 gene in one patient showing a phenotype characterize by 
non-progressive ataxia and cerebellar atrophy. In my thesis I have functionally 
characterized the mutation in patients’ fibroblast and used S. Cerevisiae as an in 
vivo model and an in silico structural model to evaluate the pathogenicity of these 
mutations. 
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Figure 9: Lon domains and oligomeric structure. (A) Functional domains of Lon 
(Pomatto, Raynes and Davies, 2017) (B) Structure of human Lon oligomer (Wong and 
Houry 2019). 
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Results 
Case report 
The patient is a 17 years old female, born at term. She presents perinatal hypoxia 
due to dystocic delivery, psychomotor delay (walked at 2.5 years) and a normal 
language development. Furthermore, she presents a non-progressive ataxia, 
nystagmus and mild dysmetria and neuroimaging showed cerebellar atrophy 
(Fig.10). Only skin biopsy was performed in patient. 
 
Figure 10: Neuroimaging studies. T1 weighted mid-sagittal section (a) and T2 
weighted coronal section (b) of the mutated patient, showing global cerebellar atrophy 
without cortical or brainstem involvement 
 
 
Mutational and structural analysis 
We performed whole-exome sequencing (WES) on genomic DNA and, after 
excluding previously annotated single nucleotide changes occurring with high 
frequency in populations (>1%), we prioritized variants predicted to have 
functional impact by using in silico programs such as Sift, Poliphen2 and Human 
Splicing Finder [HSF]. Filtering analysis allowed us to identify three different 
candidate genes overlapping patients’ phenotype: NDUFS2, QARS and LONP1. 
The first gene was excluded because we have found only one heterozygous 
mutation and is reported that mutations in this gene have a recessive inheritance. 
QUARS presented two intronic variants but the cDNA evaluation and the 
neuroimaging analysis lead us to exclude them. Finally, we found three 
heterozygous mutations in LONP1 gene. Two of these mutations were missense, 
one located in exon 12 (c.1879C>T (p.Pro627Ser)) and the other located in exon 
A B 
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18 (c.2716G>T (p.Gly906Trp)); the third was an intron variant (c.429+4A>G). 
Mutations’ segregation was confirmed using Sanger sequencing (Fig.11): the two 
missense mutations were inherited from the father, while the intron variant was 
inherited from the mother. Analysing the missense mutations using in silico 
pathogenic prediction tools (Sift, Poliphen2 and Human Splicing Finder [HSF]), 
we observed that the p.Pro627Ser is predicted as deleterious only in Sift but 
tolerated in Poliphen2; and the p.Gly906Trp was predicted as damaging in both 
programs. The intron mutation analyzed by HSF is predicted to produce an 
alteration of the WT donor site of intron 1, then affects the splicing. Both the 
missense variants are conserved in different species (Fig.12A) 
To further analyze the effect of the two missense mutations at a protein level we 
used an in silico three-dimensional structural model. From this model (Fig.12B), 
it appears that Pro627, in the ATPase domain, may be replaced by a serine without 
perturbing the protein structure. Although, a proline to serine substitution usually 
lead to a loss of thermostability and also in our case, we hypothesize that this 
destabilization cannot compromise the protein function. On the contrary, there is 
no room to accommodate a bulky tryptophan at position 906 of the functional Lon 
structure without perturbing it. Therefore, replacement of Gly906, in the protease 
domain, with a bulky tryptophan would result in clashes with other residues, 
specifically with residues of the linker between the ATPase and protease domain 
(Val753 and Glu754), unless a significant conformational rearrangement occurs. 
Such a structural change could in principle impair a proper functionality of the 
mutant. 
 
Figure 11: Electropherogram of patient and their parents. Validation of data 
obtained by WES and segregation of the different variants in the family. 
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Figure 12: Conservation and 3D structural model. (A) Multiple sequence alignment 
among species. Arrows indicate the mutated aminoacidic residues (P627S and 
G906W). (B) Structural mapping of residues affected by the missense mutations. 
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Immunoblotting, biochemical and immunocytochemistry analysis 
We performed Western blotting analysis in patient and controls fibroblast to 
evaluate the impact of the mutations on LONP1 stability and on the different 
subunits of the respiratory chain complexes (Fig.13). We observed a significative 
reduction of 50% of the protein Lon in patients compared to controls, and any 
variation in the OXPHOS subunits. Same results have been obtained using 
isolated mitochondria from fibroblast (data not shown). Although we have seen 
no reduction of the subunits of the respiratory chain complexes, therefore we 
decide to evaluate the rate of ATP synthesis in patients’ fibroblast to assess the 
functionality of the mitochondria. The CV (ATP synthase) activity was measured 
in the direction of ATP synthesis using succinate (Succ), malate (Mal) or malate 
plus pyruvate (Mal+Pyr), as substrates. Results shows a reduced ATP synthesis 
with all substrates used (Succinate: -30%, Malate: -60% and Pyruvate + Malate: 
- 60%), pointing to multiple defects of the respiratory chain complexes (Fig. 14). 
We also analyzed the distribution of the Lon protein within the cell (Fig.15), which 
typically follows the mitochondrial network but, in the patient, we have observed 
a very lower intensity of the signal. These results confirm the reduction of the 
protein, already seen in the western blot analysis. Moreover, to analyzed the 
mitochondrial network we used an antibody against TOM20, in basal condition 
and in stress condition using galactose for 24 or 48 hours, to force the cell to 
produce ATP through the OXPHOS. As we can see in Fig.16 the cells of the 
patient in basal condition show a mixed population with dot shaped, fixed and 
normal mitochondria; this different morphology of mitochondria is evident also 
in a single cell. When patients’ fibroblasts were stressed with 24h of galactose 
treatment, cells show mitochondria very similar to the cell in basal condition with 
a mixed population but we can observe a remarkable trend to a fixed network 
more than the non-treated cells; after 48h of treatment the patients’ fibroblasts 
shows a totally disorganized network with mitochondria all fixed. 
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Figure 13: Western blotting analysis. Immunoblot of total lysates from control 
subjects (Ct) and patient’s (Pt) fibroblasts using Lon, Ndufa9, SDHA, Uqcrc2, COXII, 
ATP5A1 and α-VDAC antibodies. The latter was used as loading control. Lon is 50% 
reduced and the OXPHOS subunits are normal compared to. Values in the graph are 
given as the mean ± SD (n = 3 to 4); *, p<0,05. 
 
 
 
 
Figure 14: ATP synthesis. Patient show a reduction in ATP synthesis with Succinate, 
Malate and Pyruvate+Malate. Values in the graph are given as the mean ± SD (n = 3 
to 4); ***, p<0,0005. 
 Dottorato di Ricerca in Biologia Cellulare e dello Sviluppo 
45 
 
 
Figure 15: Immunocytochemistry analysis of Lon. Analysis of the protein’s 
distribution in patients’ and controls’ fibroblast. Patient show a reduction in the signal. 
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Figure 16: Immunocytochemistry mitochondrial network. Patient’s and control’s 
fibroblast cultured in regular medium or galactose medium (24h or 48h) and marked 
with TOM20 antibody. Arrows: cells with a normal mitochondrial network; Stars: cell 
with fixed mitochondria. 
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Yeast experiments 
We used a yeast Saccharomyces cerevisiae as model to evaluate the pathogenicity 
of the mutation. PIM1 is the yeast homologous of LONP1 in human: the 
aminoacidic sequence is conserved between the two species with an identity of 
44%. To further study this model we analyze the effect of the deletion of PIM1 
(PIM1Δ) in different growth conditions, The effect of the deletion of the PIM1 
gene on growth in fermentative or respiratory media in the deleted strain and in the 
wild type 
(WT) strain has been compared (Fig.17A): the growth at the permissive 
temperature of 28°C of the deleted strain is slightly reduced in glucose but in 
glycerol medium is totally abolished. This demonstrates how PIM1 is necessary 
for the respiration of the cell and that its deletion prevents a proper mitochondrial 
functionality. It is important to note that the PIM1Δ strain is thermo-sensible: at 
non-permissive temperature of 37°C the growth is totally prevented. The oxygen 
consumption capability of the PIM1Δ strain is also completely abolished (Fig. 
17B). 
Due to the role of PIM1 in maintaining the integrity of mitochondrial genome, we 
evaluated the effect in mtDNA stability through a qRT-PCR experiment: we 
compared the level of mtDNA in the WT and in the PIM1Δ strain (Fig 17C). As 
expected, we observe a dramatic reduction of mtDNA copy number in the PIM1Δ 
strain compared to WT. 
Finally, we evaluate the functionality of the mitochondrial membrane through 
DASPMI staining (Fig 17D): this stain can identify Δψ potential defects binding 
only to active membranes. The fluorescence microscopy images reveal a 
functional mitochondrial network in the WT strain; on the contrary the PIM1Δ 
strain shows collapsed, disorganized and dysfunctional mitochondrial network. 
The transformed WT and PIM1Δ cells expressing GFP in the mitochondria 
confirm the abnormal mitochondrial distribution as collapsed wide dots in the 
deleted strain (Fig. 17E). 
To complement the PIM1 deletion the endogenous gene has been reintroduced 
into the cells by plasmid transformation. Fig. 18A shows the growth of serial 
dilutions of the WT, of the PIM1Δ mutant and of three clones transformed with 
the centromeric pC_PIM1 plasmid, in which the PIM1 was cloned with its 
promoter. The reintroduction of the PIM1 is not able to rescue the respiratory 
defect of the mutant in fact, the transformants do not grow in the respiratory 
medium. In fermentative medium the recovery of defects is observed, in particular 
at 28° C. By qRT-PCR the transcription level of the PIM1 was analysed (Fig. 
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18B): in the three transformed clones the PIM1 transcription level is higher 
compared to the WT (between 4000 and 100 times). It is possible to speculate that 
the lack of phenotypic recovery of the pC_PIM1 transformants may be due to the 
overexpression of PIM1 gene, which could be toxic for the cell. In fact, in clone 
10 the PIM1 transcription level is more similar to the WT and lower compared to 
the other two clones; in addition, also mitochondrial morphology of clone 10 is 
more similar to the WT (Fig. 18C); suggesting that this transcript level of PIM1 
could be less toxic. 
The complementation failure is also observed by qRT-PCR (Fig. 18D): compared 
to the WT the transformants show a lower number of mtDNA copies. 
By DASPMI staining it is possible to observe that the mitochondrial network of 
the transformants does not have an organized and defined structure: collapsed 
mitochondria are evident. Despite this, it is possible to note differences between 
clones 8 and 9, and clone 10: in some cells of the clone 10 the mitochondrial 
morphology is more similar to the physiological one, although many cells have 
collapsed mitochondria (Fig. 18C). We can speculate that the complementation 
failure is maybe due to an impossibility of the transformants to recover the sever 
lack of mtDNA caused by PIM deletion. To obtain the complementation of the 
phenotype other experiments are on-going and our future perspectives is to further 
evaluate the pathogenicity of our patients’ mutations with a mutagenic approach. 
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Figure 17 Phenotypic characterization of PIM1Δ yeast strain. (A) Serial dilutions of 
WT and WT deleted of PIM1 gene (PIM1 Δ) were spotted on YP plates containing 2% 
glucose or 3% glycerol (upper and lower panels, respectively) as carbon source and 
incubated at 28 and 37 °C. (B) Oxygen consumption rate, expressed as O2 nmol/ml of 
WT (black), and its derivative PIM1Δ strain (white), grown in YP 2% glucose containing 
medium. (C) qRT-PCR analysis of mtDNA level of the WT and PIM1Δ strain, grown in 
YP 2% glucose containing medium. The ratio between nuclear DNA and mtDNA mean 
values (OXI1/ACT1) was used to overcome the variability among samples caused by 
total DNA quality. **P<0.01 for deleted versus WT strain, t Student test. (D-E) 
Fluorescence microscopy of mitochondrial tubular network stained with DASPMI of WT 
and PIM1Δ strains (D) or WT and PIM1Δ expressing GFP in the mitochondrial network 
(E). Strains were grown overnight in YP 2% glucose containing medium. Star indicate 
collapsed mitochondrial network. Scale bars: 2 μm. 
A 
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Figure 18 Complementation of mitochondrial defects (A) Spot of serial dilutions of 
the WT, PIM1Δ and three transformants clones (pC_PIM1.8, .9 and .10) strains on YP 
GLU 2% and YP GLY 3% containing media at 28° C (left images) and 37° C (images 
on the right). (B) Quantification by qRT-PCR of the PIM1 transcript level of the same 
strains as above. Quantification is given by the ratio between the transcription level of 
the PIM1 gene and the housekeeping ACT1 gene. The value of the transformants has 
been divided by 1000 or by 100 to be displayed in the graph. (C) DASPMI staining of 
the mitochondrial network of the same strains as above. The red arrows show the 
representative mitochondrial morphology for each strain. (D) qRT-PCR analysis of 
mtDNA copy number of WT, PIM1Δ and transformed clones (PC_PIM1.8, .9 and .10). 
Quantification is given by the ratio between the copies number of the mitochondrial 
OXI1 and the nuclear ACT1. 
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Discussion 
Lon is a multifunctional enzyme involved in different regulatory pathways inside 
the mitochondrial matrix. It was demonstrated that attempts to get a Lonp1-/-mice 
failed (Quiros et al. 2014), as Lon inactivation is lethal at embryonic stage, 
indicating the vital importance of this protein in mammals. In our laboratory, 
through NGS technology, we found three new mutations in LONP1 gene in one 
patient with a clinical phenotype different from other described LONP1 patients. 
Mutations in this gene cause a spectrum of clinical signs ranging from bilateral 
cataract to severe neurodegenerative diseases. It has been demonstrated that 
LONP1 mutations can lead to a pathological condition known as CODAS 
(Cerebral Ocular Dental Auricular Skeletal) syndrome that, in addition, shows 
symptoms resembling a mitochondrial disease such as hypotonia and 
sensorineural hearing loss. To date, 12 missense mutations in LONP1 are 
associated with CODAS syndrome, either homozygous or heterozygous and the 
majority fall into the ATPase domain (Strauss et al. 2018); other 10 missense 
mutations were associated with congenital cataract, all were homozygous , 
mapping in the ATPase domain too (Khan and AlBakri, 2018). In 2017 was 
reported a patient with two heterozygous variants, one in the N-terminal domain 
and one in the proteolytic domain; in this case the patient presented motor 
regression, involuntary movement and cerebellar atrophy without involvement of 
skeletal or dental symptoms; these features have never been reported in CODAS 
syndrome but are more indicative of a mitochondrial disease (Inui et al., 2017). 
Finally, in 2018, Peter et al. reported compound heterozygous missense mutations 
in LONP1, both located in the ATPase domain, in a patient characterized by a 
classic mitochondrial phenotype, with Leigh syndrome, lactic acidosis, 
respiratory distress, reduced movement and a severe multiple OXPHOS defects. 
More recently, two siblings have been reported with a homozygous missense 
variant in the protease domain of LONP1 associated with a severe 
neurodegenerative phenotype, presenting a progressive cerebral and cerebellar 
atrophy, developmental delay and, in one of the two siblings, seizures refractory 
too (Nimmo et al., 2019). 
The patient here described is characterized by psychomotor delay, non-
progressive ataxia, nystagmus and severe cerebellar atrophy. Therefore, the 
clinical phenotype of our patient is milder than the one previously reported 
(Strauss et al. 2015; Peter et al, 2018; Nimmo et al.2019). In patient’s fibroblasts, 
we observed that LONP1 mutations cause defects in mitochondrial functionality 
and morphology. Moreover, the alterations of mitochondrial network are more 
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evident after galactose administration, indicating that Lon is fundamental to 
maintain mitochondrial homeostasis. Our results are in line with the previously 
reported electron microscopy imaging that showed abnormal mitochondria 
(Nimmo et al. 2019). In addition, western blot analysis revealed a 50% reduction 
of Lon, which can be due to the splicing mutation; this variant could produce an 
exon skipping that can lead to a decay of the mRNA and/or to a degradation of 
the protein. 
We can speculate that the intronic variant, which affects the total amount of the 
protein, lead to a loss of function resulting in a less severe phenotype. 
We are deeply investigating the missense mutations in the yeast model, in order 
to better characterize the variants’ effect. In conclusion, the features of our patient 
expand the clinical phenotype caused by mutations in LONP1. 
 
Methods 
Standard protocol approvals, registrations and patients consents 
The study was approved by the Ethical Committees of the Bambino Gesu` 
Children’s Hospital, Rome, Italy, in agreement with the Declaration of Helsinki. 
Informed consent was signed by the parents of the patients. 
Mutational analysis 
Exome capture and massively parallel sequencing were outsourced (BGI, Shen-
zhen, China) using Sure Select Human All Exon V.4 Agilent and deep Illumina 
Hiseq technology (median reads depth= 50×). Called variants were filtered to 
retain variants with a quality score (Qs) > 30. High- quality variants were then 
filtered against public databases (dbSNP142 and ExAC v.0.3) to retain novel and 
clinically associated variants, and annotated variants with unknown frequency or 
having MAF< 1%. Variants prioritization was performed valuating their 
functional impact, using in silico programs for mutations (Sift, Poliphen2 and 
Human Splice Finder). All variants identified by NGS were validate by Sanger 
Sequencing as well the segregation in the family. 
Structural model 
A model for the ATPase and protease domains of LONP1 was built by Modeller 
using the coordinates of the experimental structure of its catalytic (C-terminal) 
domain, from Met756 to Glu953 (PDB ID: 3x36, resolution 2 Å), and the structure 
of Lon protease from Bacillus subtilis bound to ADP (PDB ID: 3m6a, resolution 
3.4 Å, sharing with human LONP1 a sequence identity of 46%), as a template for 
the ATPase domain (residues Ala416-Arg755) and its orientation relatively to the 
protease domain. Models for the P627S and G906W point mutants were obtained 
with the mutagenesis tool of PyMol, starting from the coordinates of the wild-type 
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model. 
Immunoblotting and Immunostaining 
Human fibroblasts were obtained from a diagnostic skin biopsy and grown in 
DMEM medium supplemented with 10% fetal bovine serum, 4.5 g/L glucose, and 
50 μg/mL uridine. 
For SDS-PAGE, 40 μg of fibroblasts homogenate were loaded in a 12% 
denaturating gel. Western blot (WB) was achieved by transferring proteins onto 
polyvinylidene difluoride (PVDF) membrane and probed with specific antibodies. 
Specific bands were detected using Lite A blot Extend Long Lasting 
Chemiluminescent Substrate (Euroclone, Pero (Mi), Italy). Densitometry analysis 
was performed using Quantity One software (BioRad, Hercules, CA, USA). RCC 
subunits were detected using the following monoclonal antibodies purchased 
from MitoScience (Eugene, OR, USA): Complex I – NDUFA9; complex II – 
SDHA; complex-III - UQCRC2; complex IV – COXII; Complex V – ATP5A1; 
porin (VDAC). anti-LONP1 (Novus Bio) 1:500 was also used. 
To display the mitochondrial network arrangement, fibroblasts from Patient were 
fixed and permeabilized using methanol:acetone (2:1) for 10 min at room 
temperature, then a blocking solution containing 5% BSA in PBS was used. The 
polyclonal rabbit TOMM20 antibody (Santa Cruz Biotechnology) was applied 
overnight and visualized using Alexa Fluor 647 secondary antibody (Jackson 
Immuno Research), both antibodies were used at the dilution of 1:500. Images 
were acquired with a fluorescence inverted microscope (Leica DMi8). An average 
of 8 image planes was obtained along the z-axis at 0.2 µm increments using LASX 
3.0.4 (Leica) software. 
To display the LONP1 network cells were fixed in paraformaldehyde (PFA) 4% 
for 10’ at room temperature (RT) and permeabilized in triton 0.1% + FBS 5% 
diluted in phosphate buffer saline (PBS) for 20’. After blocking in bovine serum 
albumin (BSA) 5% for 1h at RT, a primary antibody anti-LONP1 (Novus Bio) 
1:100 + NGS 1% in PBS were added overnight at 4°C. After three wash in PBS 
5’ an Alexa Fluor 647 secondary antibody (Jackson ImmunoResearch) 1:500 + 
NGS 3% in PBS for 1h at 37° was applied. After three wash in PBS 5’ nucleous 
were stained with Hoechst- 33342 1:10000 for 5’ and then the coverslip was 
mounted in PBS/Glicerol 1:1. Images were acquired with a fluorescence-inverted 
microscope (Leica DMi8). An average of 8 image planes was obtained along the 
z-axis at 0.2 μm increments using LASX 3.0.4 (Leica) software. 
ATP synthesis 
ATP synthesis was assayed spectrophotometrically. In brief, about 300 μg 
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mitochondrial proteins were incubated in 20 mM Tris–HCl, pH 7.5, 150 mM 
sucrose, 1 mM ADP, 20 mM phosphate, 5 mM MgCl2, 100 μM di-adenosine 
pentaphosphate, 10 mM glucose, 30 U of hexokinase, and one of the following: 
50 mM succinate, 6 mM malate, 6 mM α-ketoglutarate or 12 mM/1.2 mM 
pyruvate/malate, at 37°C for 20 min in vials with vigorous stirring to ensure 
maximum oxygenation. The reaction was stopped with 25 mM EDTA + 2 μM 
carbonyl cyanide 3- chlorophenylhydrazone (CCCP), followed by transfer to ice-
cold water. The synthesized glucose 6-phosphate was oxidized by NADP in the 
presence of 30 units of glucose 6-phosphate dehydrogenase. NADPH formation 
was monitored at 340 nm. Under these experimental conditions, a 1:1 ratio was 
found between the ATP synthesized and the NADPH formed. Protein content was 
measured by BCA (Pierce, USA) and read at 562 nm. 
Yeast experiments 
Yeast strains used to perform experiments described in this thesis were the D273–
10B/A1 (MATα, met6, ura3-52; Sherman e Slonimski, 1964) rho+ (with mtDNA 
wild type). The PIM1 null strain (PIM1Δ) was obtained by transformation of 
D273–10B/A1 (MATα, met6, ura3-52) rho+ with the Kan-MX4 cassette as 
already described (Montanari et al., 2013). 
Strains were grown on YP complete medium (1% yeast extract and 1% peptone 
from Difco) containing, 2% glucose or 3% glycerol or in minimal medium (0.17% 
yeast nitrogen base -Difco, 0.5% ammonium sulfate and 2% glucose), 
supplemented with the necessary auxotrophic requirements according to the 
phenotype of the strains. For plates, 2% agar was added to the medium. Growth 
capability was investigated by serial dilutions from concentrated suspensions 
(5×106 cell/ml) prepared from fresh single colony spotted onto YP agar plates 
containing 3% glycerol or 2% glucose. Pictures were acquired after 2–3 days of 
growth on glucose plates and after 5 days of growth on glycerol plates. 
Transformation of yeast strains was obtained by the lithium acetate method (Gietz 
and Woods, 2014). To control PIM1 deletion, colony PCR has been performed. 
Cells were resuspended in 100 μl of LiAc 0.2 M + SDS 1%. After incubation at 
70° C for 15 min, 300 μl of EtOH were added. After vortexing and centrifugation 
at 13,000 rpm for 3 min, the supernatant was removed and the pellet was 
resuspended in 100 μl of TE 1X. Vortex again and centrifuge at 1,000 rpm for 1 
min. PCR protocol using 3PIM1+ / KANRev primers was as follow: 5’ at 95°C; 
40 X (30 sec at 95°C;, 40 sec at 60 °C, 1 min at 72°C); 1 min at 72°C . 
Standard protocols (Sambrook et al, 1989) were used for restriction enzyme 
digestions as well as plasmid preparations. 
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To produce pC_PIM1 plasmid, PCR amplification using 3’PIM1+ and 5’PIM1- 
was performed to clone PIM1 gene with its promoter in the commercial 
pCR2.1TOPO plasmid (Invitrogen). The insert was successively subcloned in the 
centromeric pRS416 plasmid by KpnI/XhoI digestion. 
Respiration studies were performed using a Clark oxygen electrode (Hansatech 
Instruments). After overnight growth in YP 2% glucose containing medium at 
28°C cells were washed with 1 ml sterile water. After centrifugation the pellet, 
corresponding approximately to 0.03 g (wet weight) of cells, was suspended in 1 
ml of phosphate buffer10 mM, pH 7.4 containing 0.4% glucose and loaded in the 
Reaction Vessel of the previously calibrated Oxygen Electrode Chamber. The 
endogenous oxygen consumption was measured for 10 min. 
To quantify the numbers of mtDNA copies we performed a quantitative Real 
Time-PCR (qRT- PCR) assay using 2X SYBR-green master mix (Bioline) and 
primers for the mitochondrial OXI1 gene and ACT1 gene as a housekeeping gene. 
For RT-PCR experiments the total RNA extraction, cDNA generation, sample 
preparation and amplification reaction were performed as previously described 
(Montanari, Francisci 2017). 
For detection of mitochondrial morphology yeast cells were transformed with 
multi-copy plasmid, pVT100U bearing the GFP gene with the mitochondrial 
presequence of ATPase subunit 9 of Neurospora crassa fused at 5’-end 
(Westermann and Neupert, 2000). To visualize mitochondrial functionality, we 
used DASPMI [2-(4-(dimethylamino)steryl)-1-methylpyridinium iodide], a vital 
staining that reveals mitochondrial functional membranes. Image were acquired 
in the Zeiss Axio Imager Z1 Fluorescence Microscope and elaborated through an 
Axio-Vision 4.8 Digital Image Processing System and objective lens 63× oil. 
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Oligonucleotides: 
PIM1Kan+ 5’-
GGTTTTCGAGGTGCTTGAACGAAAAGATTTGCAAATAGAGCGT
ACGCTGCAGGTCGAC-3’ 
PIM1Kan- 5’-
CAGAATGTTTAAACAGGTATTTAATCCATTTAGATGAAAAGTTC
GACACTGGATGGCGGC-3’ 
3’PIM1+ 5’-TCTTCGGTAAGTAATTAGATTTC-3’ 
5’PIM1+ 5’-GTAGATCGCAAAAGTTGCTAG-3’ 
KANRev 5’-TCATGCCCCTGAGCTGCG-3’ 
PIM1.2+ 5’-TGACAGAAGATGCAATAACAG-3’ 
PIM1.2- 5’-CTTTCTTTAGGCTTGCTGTC-3’ 
ACT1+ 5'-ACGTTCCAGCCTTCTACGTTTCCA-3' 
ACT1- 5'-AGTCAGTCAAATCTCTACCGGCCA-3' 
OXI1+ 5'-GTACCAACACCTTATGCAT-3' 
OXI1- 5'-CATTCAAGATACTAAACCTAA-3' 
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General conclusions and future perspective: 
In my project I analyzed different patient presenting with different subtype of 
mitochondrial diseases; the use of Next Generation Sequencing technology, in the 
last years, has expanded the genetic diagnosis of many unsolved cases with 
mitochondrial disorders, with an increased diagnostic success, from <20% to 
>60% (Gorman et al., 2016). 
In my project I analyzed two different pathways involved in mitochondrial 
homeostasis. These pathways can actually underpin two mechanisms known as 
mitochondrial dynamics and quality control; both the proteins are involved in 
maintaining mitochondrial health and functionality. In particular, Drp1 is the main 
responsible of mitochondrial fission, a fundamental process during development; 
in fact, it drives a correct distribution of mitochondria during cellular division. On 
the other hand, Lon is a multifunctional protease involved in mitochondrial 
quality control and that take part to different mechanism such as mitochondrial 
and cellular proteostasis, mitochondrial DNA stability and folding of some of the 
subunits of the respiratory chain complexes (e.g. COXI, COXIV). Both, the 
murine model of DNM1L and LONP1 homozygous knockout results to be 
embryonically lethal, underling the fundamental role of these two proteins in the 
whole physiology of mammals.  
In the first part of my thesis I have characterize five patients with different 
mutations in DNM1L gene and, using different approaches, I have demonstrated 
that all mutations are pathogenetic; Next Generation sequencing technology was 
an useful tool, not only to identified the new different variant, but also to deeply 
investigate the variant of the patient 4, allowing us to demonstrate that was a 
germinal mosaicism of the mother, otherwise we had lack this information. It is 
important to note that we had demonstrated for the first time a particular feature 
of the muscular biopsy of patient mutated in DNM1L and that can be useful in the 
future to accelerate the diagnosis of patients presenting such phenotypic signs.  
In the second part of my thesis I have characterized one patient with three different 
mutation in LONP1 gene; this gene was already reported as the cause of very 
different pathology conditions such as CODAS syndrome or other type of disease 
that resemble a more classical mitochondrial disease. We here describe a patient 
with a milder phenotype in respect to the already referred patients. As already 
reported, we believe that different pathogenic Lonp1 variants may confers specific 
defect in protein degradation and can lead to different organ-specific dysfunction. 
Since there are no effective curative treatments in mitochondrial diseases, the 
individuation of disease-associated variants is of key importance and can lead us 
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to study, in the near future, specific therapeutic approaches that can modulate the 
functionality of these mutated proteins.  
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Synopsis 
Mitochondria are subcellular organelles found in all eukaryotic cells, except in 
red blood cells; they are implicated in multiple cellular processes and consist of 
two membranes, the inner mitochondrial membrane (IMM) and the outer 
mitochondrial membrane (OMM), and of two aqueous compartments, the matrix 
and the intermembrane space. The IMM area is several-fold larger than the one of 
OMM, due to the fact that in the IMM there are some invaginations called cristae 
which contain the electron transport chain complexes from I to IV (complex I, CI; 
complex II, CII; complex III, CIII; complex IV, CIV) and the F1-F0-ATP 
synthase (CV). This multicomplex system is responsible for energy production, 
in the form of adenosine 5′-triphosphate (ATP), via the oxidative phosphorylation 
(OXPHOS). 
In addition to energy production, mitochondria are involved in many biological 
functions, including the regulation of reactive oxygen species (ROS), biogenesis 
of the Fe-Cu clusters, heme synthesis, metabolism of amino acids and lipids, 
apoptosis and mitophagy (Gorman et al. 2016). Given their fundamental role in 
the physiology of the whole cell, mitochondria undergo to a tightly regulation, 
since any of their dysfunction can lead to dramatic consequences 
Mitochondrial diseases (MDs) are a group of very heterogeneous and rare genetic 
disorders that affect mitochondrial respiratory chain function and cellular energy 
production. MDs can arise from both nuclear or mtDNA mutations, can occur at 
any age and, although the most affected tissues are those with high energy demand 
such as brain, muscle and heart, the clinical signs could involve also liver, heart, 
kidney, eye and ear (ref). The incidence of MDs is 1:5000 live birth (Gorman et 
al., 2016; Craven et al., 2017) considering only the mutation that affect the 
mtDNA and even higher by including some frequent nuclear gene mutations, 
reaching the incidence of 1:2000 individuals (Suomalainen and Battersby, 2018). 
In the last years, the breakthrough of next-generation sequencing (NGS) 
approaches for genetic diagnosis has expanded the genetic heterogeneity of MDs 
(Stenton and Prokisch, 2018). 
The maintenance of “healthy” and fully functional mitochondria is essential for 
cellular homeostasis. In this regard, the cell has evolved various mechanisms 
dedicated to the maintenance of the mitochondrial proteome such as 
mitochondrial dynamics and mitochondrial quality control. A first check point 
and active surveillance is provided by the organelle itself. The mitochondria have 
their own chaperones and proteolytic enzymes that remove damaged or unfolded 
proteins (Matsushima and Kaguni, 2012). The plasticity of the mitochondria 
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allows continuous changes of their shape and number, while their morphology is 
maintained by the equilibrium of fusion and fission event. 
Mitochondria undergo fusion and fission in order to avoid damage accumulation 
or respond to certain bioenergetics demands (Campello and Scorrano, 2010). In 
recent years, a significant number of mutations in genes involved in mitochondrial 
dynamics and mitochondrial quality control have been recognized as the genetic 
cause of MDs. 
In our laboratory through the use of Next Generation Sequencing (NGS) 
technology we identify new mutations in genes involved in mitochondrial 
dynamics and in mitochondria quality control and we have functionally 
characterized these mutations and demonstrated their pathogenic roles in the 
analyzed patients. 
In the first part of my thesis I focused my attention in the pathway of 
mitochondrial dynamics; this mechanism is controlled by a set of dynamin’s 
family members, the large guanosines triphosphate hydrolases (GTPases) that are 
well conserved between yeast, flies, and mammals. Fission is mediated by a 
cytosolic dynamin family member called Drp1, encoded by DNM1L gene. When 
activated DRP1 is recruited by the mitochondrial dynamics’ proteins 49 and 51 
kDa (MiD49 and MiD51), and the mitochondrial fission factor (Mff) to the outer 
mitochondrial membrane, where it binds its receptor, the mitochondrial fission 
protein 1 (Fis1) and multimerizes, creating a ring-like structure that constricts and 
divides the organelle five patients presenting with epileptic encephalopathy The 
use of NGS technology allowed us to described five patients with different 
missense mutations in DNM1L gene and, using different approaches, I have 
demonstrated that all mutations are pathogenetic. Probably the most peculiar 
finding in the cohort of our patients is the muscle histology/histochemistry 
showing core like areas using oxidative enzyme staining for COX and SDH, 
which suggest an abnormal distribution of mitochondria in the muscle tissue. We 
found this pattern in all the examined muscle biopsies. Moreover, in serial 
sections of muscle fibers of Pt.3 we demonstrated that the fibers that are no 
reactive for COX, SDH and NADH are also negative for the staining with ATPase 
9.4 indicating that these are type I muscular fibers. 
In the second part of my thesis I study another pathway called mitochondrial 
quality control that is a mechanism involved in the maintenance of mitochondrial 
health and function. A set of chaperones and proteases, belonging to the AAA+-
proteases (ATPases Associated with diverse cellular Activities) family, located in 
different mitochondrial compartment controls the biosynthesis, folding or 
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degradation of misfolded proteins. Lon, in the mitochondrial matrix, acts mainly 
as a protease but also as a chaperone to guide the folding of several respiratory 
chain complexes subunits (Rep et al., 1996). Moreover, it can regulate the stability 
of the mtDNA, directly binding it (Fu, Smith & Markovitz, 1997) or indirectly 
regulating the degradation of the main transcription factor of the mtDNA, TFAM 
(Lu et al., 2007). LONP1 mutations have been associated to a severe disease, 
known as CODAS (Cerebral, Ocular, Dental, Auricular, Skeletal anomalies) 
(Shebib et al., 1991; Strauss et al., 2015) (OMIM #600373). Only recently LONP1 
mutations have been recognized as the genetic cause of a subtype of mitochondrial 
disease (Peter et al., 2018; Nimmo et al., 2019). 
In our laboratory through the use of NGS technology I identify three different 
mutations in LONP1 gene in one patient showing a phenotype characterize by 
non-progressive ataxia and cerebellar atrophy. In my thesis I have functionally 
characterized the mutation in patients’ fibroblast and used S. Cerevisiae as an in 
vivo model and an in silico structural model to evaluate the pathogenicity of these 
mutations. In patient’s fibroblasts, we observed that LONP1 mutations cause 
defects in mitochondrial functionality and morphology. Moreover, the alterations 
of mitochondrial network are more evident after galactose administration, 
indicating that Lon is fundamental to maintain mitochondrial homeostasis. We are 
now deeply investigating the missense mutations in the yeast model, in order to 
better characterize the variants’ effect. In conclusion, the features of our patient 
expand the clinical phenotype caused by mutations in LONP1. 
In conclusion the use of NGS technology, in the last years, has expanded the 
genetic diagnosis of many unsolved cases with mitochondrial disorders and, since 
there are no effective curative treatments in mitochondrial diseases, the 
individuation of disease-associated variants is of key importance and a basic 
understanding of the molecular mechanism involved in these mitochondrial 
pathways can lead us to study, in the near future, specific therapeutic approaches 
that can modulate the functionality of these mutated proteins. 
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